These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20809642)

  • 1. Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.
    Trabocchi A; Menchi G; Cini N; Bianchini F; Raspanti S; Bottoncetti A; Pupi A; Calorini L; Guarna A
    J Med Chem; 2010 Oct; 53(19):7119-28. PubMed ID: 20809642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.
    Trikha M; Zhou Z; Timar J; Raso E; Kennel M; Emmell E; Nakada MT
    Cancer Res; 2002 May; 62(10):2824-33. PubMed ID: 12019160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
    Nam JO; Jeong HW; Lee BH; Park RW; Kim IS
    Cancer Res; 2005 May; 65(10):4153-61. PubMed ID: 15899806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosynthesis and micro-SPECT analysis of triazole-based RGD integrin ligands as non-peptide molecular imaging probes for angiogenesis.
    Bianchini F; Fabbrizzi P; Menchi G; Raspanti S; Bottoncetti A; Passeri A; Andreucci E; Guarna A; Calorini L; Pupi A; Trabocchi A
    Bioorg Med Chem; 2015 Mar; 23(5):1112-22. PubMed ID: 25637121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
    Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
    Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity.
    Cini N; Trabocchi A; Menchi G; Bottoncetti A; Raspanti S; Pupi A; Guarna A
    Bioorg Med Chem; 2009 Feb; 17(4):1542-9. PubMed ID: 19195898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing for integrin alpha v beta3 binding of RGD peptides using fluorescence polarization.
    Wang W; Wu Q; Pasuelo M; McMurray JS; Li C
    Bioconjug Chem; 2005; 16(3):729-34. PubMed ID: 15898744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo.
    Silletti S; Kessler T; Goldberg J; Boger DL; Cheresh DA
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):119-24. PubMed ID: 11134507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
    Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
    J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties.
    Maeshima Y; Colorado PC; Kalluri R
    J Biol Chem; 2000 Aug; 275(31):23745-50. PubMed ID: 10837460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell surface proteolysis by serine proteinases enhances RGD-sensitive melanoma cell adhesion on fibrinogen and vitronectin.
    Fujii K; Imamura S
    Exp Cell Res; 1995 Sep; 220(1):201-11. PubMed ID: 7545129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight to the binding mode of triazole RGD-peptidomimetics to integrin-rich cancer cells by NMR and molecular modeling.
    Vasile F; Menchi G; Lenci E; Guarna A; Potenza D; Trabocchi A
    Bioorg Med Chem; 2016 Mar; 24(5):989-94. PubMed ID: 26818999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.
    Trikha M; Zhou Z; Nemeth JA; Chen Q; Sharp C; Emmell E; Giles-Komar J; Nakada MT
    Int J Cancer; 2004 Jun; 110(3):326-35. PubMed ID: 15095296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ¹²⁵I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand of αvβ₃ integrin as a molecular imaging probe for angiogenesis.
    Bianchini F; Cini N; Trabocchi A; Bottoncetti A; Raspanti S; Vanzi E; Menchi G; Guarna A; Pupi A; Calorini L
    J Med Chem; 2012 Jun; 55(11):5024-33. PubMed ID: 22621422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells.
    Allman R; Cowburn P; Mason M
    Eur J Cancer; 2000 Feb; 36(3):410-22. PubMed ID: 10708944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).
    Zannetti A; Del Vecchio S; Iommelli F; Del Gatto A; De Luca S; Zaccaro L; Papaccioli A; Sommella J; Panico M; Speranza A; Grieco P; Novellino E; Saviano M; Pedone C; Salvatore M
    Clin Cancer Res; 2009 Aug; 15(16):5224-33. PubMed ID: 19671851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
    Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
    Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
    J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
    Wong A; Hwang SM; McDevitt P; McNulty D; Stadel JM; Johanson K
    Mol Pharmacol; 1996 Sep; 50(3):529-37. PubMed ID: 8794891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.